ABT
Not exactly a vote of no confidence
Border to Coast Pensions Partnership Ltd cut its Abbott Laboratories stake by 14%, selling 59,329 shares and still holding about 363,027 shares worth roughly $45.57 million. That’s the kind of move that can nudge the tape, but it’s not exactly the financial version of setting your house on fire and walking away.
The real story is still the quarter
The filing lands on the same day Abbott reported quarterly EPS of $1.50, which came in right on estimates, while revenue of $11.46 billion slipped a bit below Wall Street’s target. In other words: not a blowout, not a disaster, just a slightly soggy landing.
Insiders were busy too
There was also some insider activity in the mix. Director Daniel J. Starks bought 10,000 shares at an average price of $108.73, while insiders collectively sold 3,055 shares during the quarter. So you’ve got one big institution trimming, one director buying, and the usual corporate ownership choreography happening in the background.
Why you should care
Abbott also guided Q1 2026 EPS to $1.120–$1.180 and full-year 2026 EPS to $5.550–$5.800, which is the part investors will actually stare at after the headline fades. Big picture: this isn’t just about one pension manager selling. It’s about whether Abbott can keep turning a steady-medical-device machine into steady stock performance.